GSK Bets $10.6 Billion on Lung Cancer Pipeline Expansion

A 40% premium over Nuvalent’s closing price anchors GSK’s $10.6 billion acquisition, a move designed to secure the pharmaceutical giant’s future against the looming 2028 patent expiration of its blockbuster HIV drug, dolutegravir. The deal grants the British firm control over a specialized portfolio of precision oncology treatments.

Editorial·June 9, 2026·reads: 2,050

GSK Bets $10.6 Billion on Lung Cancer Pipeline Expansion

GSK’s strategic pivot centers on integrating Nuvalent’s research into its existing oncology framework, specifically targeting the expansion of Ris-Rez, an experimental antibody-drug conjugate currently navigating late-stage clinical trials. By absorbing Nuvalent at $124 per share, the company aims to solidify its position in the competitive lung cancer market while diversifying its revenue streams before its HIV portfolio faces generic competition.

Chief Commercial Officer Luke Miels noted that the acquisition serves as a platform for long-term growth, rather than a singular product play. Financial projections from the company place the net investment at $9.4 billion after accounting for existing cash holdings. Management anticipates the investment will begin bolstering sales and operating profits by 2027, with a positive impact on core earnings per share projected by 2029.